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Abstract
Background: Estrogen deficiency is closely related to the development of menopausal arthritis. Estrogen
replacement therapy (ERT) shows a protective effect against the osteoarthritis. However, the underlying mechanism
of this protective effect is unknown. This study aimed to determine the role of miR-140 in the estrogen-dependent
regulation of MMP-13 in human chondrocytes.
Methods: Primary human articular chondrocytes were obtained from female OA patients undergoing knee
replacement surgery. Normal articular chondrocytes were isolated from the knee joints of female donors after
trauma and treated with interleukin-1 beta (IL-1β). Gene expression levels of miR-140, MMP-13, and ADAMTS-5 were
detected by quantitative real-time PCR (qRT-PCR). miR-140 levels were upregulated or downregulated by
transfecting cells with a miRNA mimic and inhibitor, respectively, prior to treatment with IL-1β. MMP-13 expression
was then evaluated by Western blotting and immunofluorescence. Luciferase reporter assays were performed to
verify the interaction between miR-140 and ER.
Results: 17-β-estradiol (E2) suppressed MMP-13 expression in human articular chondrocytes. miR-140 expression
was upregulated after estrogen treatment. Knockdown of miR-140 expression abolished the inhibitory effect of
estrogen on MMP-13. In addition, the estrogen/ER/miR-140 pathway showed an inhibitory effect on IL-1β-induced
cartilage matrix degradation.
Conclusions: This study suggests that estrogen acts via ER and miR-140 to inhibit the catabolic activity of proteases
within the chondrocyte extracellular matrix. These findings provide new insight into the mechanism of menopausal
arthritis and indicate that the ER/miR-140 signaling pathway may be a potential target for therapeutic interventions
for menopausal arthritis.
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Background
Osteoarthritis (OA) is the most common articular path-
ology and is the leading cause of mobility-associated dis-
ability, which is characterized by pain, tenderness,
limited movement, crepitus, and a variable degree of
inflammation without systemic effects [1]. The patho-
genesis of OA is complex and involves the interaction of
multiple factors. Among these factors, sex hormones
play critical roles in OA pathogenesis in women over 50
years old or after menopause. The ‘arthritis of meno-
pause’ phenomenon, where OA incidence rises steeply
with age after menopause [2–4], was described as early
as 1926. The prevalence of OA increases in women with
menopausal transition and is thought to be due to a re-
duction of estrogen levels [5, 6]. However, the effect of
estrogen replacement in OA patients and the correlation
between estrogen and OA are unclear [7–9]. Several
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studies report that estrogen exerts a chondroprotective
effect, while others present evidence of a chondrodes-
tructive effect or no effect on cartilage. OA is charac-
terized by degradation of extracellular matrix (ECM)
macromolecules by proteolytic enzymes produced by ac-
tivated chondrocytes, including matrix metallopeptidase
13 (MMP-13) [10–12].
Both estrogen receptor (ER) and MMP-13 are expressed
in joint tissue and chondrocytes, indicating that chon-
drocytes can respond to estrogen treatment [13, 14].
However, studies on the effect of ovariectomy (OVX) and
estrogen treatment on cartilage in animal models of OA
were inconclusive [15]. Gene expression of some extra-
cellular matrix molecules was inhibited by estrogen.
Physiological levels of estrogen decreased MMP-1 expres-
sion and increased proteoglycan synthesis in chondrocytes
[15, 16]. MMP-13 microRNA (mRNA) levels were signifi-
cantly suppressed by 17-β-estradiol (E2) in articular chon-
drocytes of female patients [17]. Further investigation is
needed to understand the mechanisms underlying the ef-
fect of estrogen on matrix proteases and to develop effect-
ive therapeutic targets for OA.
miRNAs are a class of abundant, small, highly con-
served noncoding RNA (approximately 22 nucleotides)
found in higher eukaryotes. They act as multifunctional
mediators of biological processes by partially base-
pairing with mRNA sequences of target genes in the 3′-
untranslated region (UTR) [18, 19], thus contributing to
posttranscriptional regulation of gene expression. Accu-
mulating data have demonstrated that miRNAs are critical
for pathogenesis developmental and cellular processes, in-
cluding organogenesis and differentiation [20–22]. Re-
cently, miRNA families have been shown to target genes
expressed in cartilage and have therefore been studied to
elucidate their involvement in cartilage tissue develop-
ment, homeostasis, and degradation [23–26]. A select
number of miRNAs play key roles in the development of
OA [27, 28]. For example, miR-140 directly targets the
gene that encodes a disintegrin and metalloproteinase
with thrombospondin motifs 5(ADAMTS-5), an aggreca-
nase that cleaves aggrecan in cartilage. miR-140 is also a
negative regulator of MMP-13, and miR-140 expression is
downregulated in OA [29–32]. However, the mechanism
that underlies miR-140-mediated regulation upstream of
its effects on ADAMTS-5 and MMP-13 is currently un-
clear. The transcription factors involved in miR-140 ex-
pression in OA pathogenesis are also unknown.
ER is a ligand-activated transcription factor that regu-
lates target genes at both transcriptional and posttran-
scriptional levels. For example, following estrogenic
activation, ER directly regulates the transcripts of some
target genes via DNA binding [33]. In contrast to hor-
monally regulated transcription, which has been exten-
sively described at the molecular level, regulation of
miRNA by estrogenic activation of ER has not been
widely studied [34].
In this study, we sought to determine whether estro-
gen regulates MMP-13 expression and interleukin-1 beta
(IL-1β)-induced catabolic responses in human chondro-
cytes. Our results demonstrate that miR-140 acts as an
intermediary transcriptional factor to suppress MMP-13
and IL-1β responses in human chondrocytes. Thus,
miR-140 may be a regulator of cartilage homeostasis in
OA. Estrogen-bound estrogen receptor alpha (ERα) was
shown to initiate the transcription of miR-140 by associ-
ating with its ER response element (ERE) element.
Methods
Primary chondrocytes culture
The donation of cartilage was approved by the ethics
committee at the Medical Faculty at Shenzhen Second
People’s Hospital. Informed consent had been obtained
from cartilage donors. OA cartilage samples was ob-
tained from nine female patients (mean age > 53 years)
who underwent joint replacement or joint surgery in the
department of Orthopedics, Shenzhen Second People’s
Hospital. Articular cartilage tissues were cut into small
fragments (1–2 mm3), and followed by digestion with 1
mg/mL collagenase (Sigma-Aldrich, St. Louis, MO,
USA) for 16 h at 37 °C with shaking. After dissociation,
the triturate suspension was filtered through a 100-mm
nylon cell strainer (Falcon, BD, Oxford, UK) to remove
matrix debris, and cells were collected by centrifugation
at 800 × g for 10 minutes. Chondrocytes were then re-
suspended in Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 medium (Gibco, Invitrogen, Carlsbad,
CA, USA), supplemented with 10 % fetal bovine serum
(FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin
(Gibco). Primary cultures of human chondrocytes and
treatment passage 0 cells were subcultured after 5–7
days of isolation and either used directly (P1 cells) or
passaged once more (P2 cells) before experiments.
Chondrocytes were serum starved overnight and then
treated with 5 ng/mL recombinant human IL-1β (Pepro-
Tech, London, UK) or E2 for the indicated periods of
time. Chondrocytes were placed in monolayer culture in
12-well plates (for RNA) or 6-well plates (for protein).
Transfection experiments were performed 1 day after
seeding.
Treatment with IL-1β and estrogen
For OA chondrocytes from female patients, primary OA
chondrocytes at 80 % confluence were used for the ex-
periments. These cells were incubated with indicated
concentration of E2 (Sigma E-8875, Sigma-Aldrich).
Stock solutions of 10−1M E2 in absolute ethanol were
prepared and diluted stepwise. Controls were incubated
with 0.1 % ethanol instead of the hormones. For normal
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chondrocytes from trauma patients (n = 3), primary cul-
tured human chondrocytes were serum starved over-
night and then treated with recombinant human IL-1β
(5 ng/mL; PeproTech) for the indicated periods of time
for incubations with estradiol.
RNA extraction, reverse transcription, and quantitative
real-time (RT)-PCR
Total RNA from human articular chondrocytes was ex-
tracted with TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. Then 1 μg total RNA was
reverse-transcribed with a specific stem-loop primer for
miRNA and with a random primer for messenger RNA
(mRNA) using reverse transcription kits (Takara Bio-
technology, Dalian, China), respectively. The mRNA ex-
pression was analyzed using qRT-PCR with Sybr Green
premix (Takara Biotechnology). For the reverse tran-
scription step, a miRNA-specific stem-loop primer (=
looped primer) was used (5 pmol in 20 μl reaction vol-
ume) to generate cDNA. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and small nuclear RNA U6
were used as internal controls for complementary DNA
(cDNA) and miRNA, respectively [35]. Primer sequences
used for qRT-PCR are listed in Table 1.
Immunofluorescence microscopy
Immunostaining to detect expression of MMP-13 in
chondrocytes was performed using standard protocols.
Chondrocytes were cultured on coverslips under differ-
ent treatment. Briefly, cells were fixed with 4.0 % para-
formaldehyde (Sigma-Aldrich) and permeabilized with
0.1 % Triton X100 for 10 min (Sigma-Aldrich) in
Dulbecco’s phosphate-buffered saline (Invitrogen). Non-
specific binding was blocked with 10 % goat serum, and
cells were incubated overnight with MMP13 primary
antibody at a dilution of 1:200. After washing, the cells
were incubated with anti-mouse Alexa Fluor 594
(Invitrogen) secondary antibodies (1:300) for 1 h at room
temperature. Coverslips were mounted on slides and ob-
served using a fluorescent microscope. We used DAPI
(Sigma-Aldrich; 1 μg/ml) for nuclear staining.
Western blotting
Cells were lysed with lysis buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 % NP- 40, and 0.1 % sodium dodecyl
sulfate) supplemented with protease inhibitor cocktail set
I (Biotool, Jupiter, FL, USA) and phenylmethanesulfonyl
fluoride (PMSF, Sigma-Aldrich), and the concentration
was measured using the BCA protein assay kit (Pierce,
Rockford, IL, USA) using bovine serum albumin as the
standard. Proteins were fractionated by SDS polyacryl-
amide gel electrophoresis and transferred onto a PVDF
membrane. The membrane was blocked with 5 % nonfat
dry milk in Tris-buffered saline containing 0.1 % Tween
20. MMP13 protein was detected by Western blotting
using a polyclonal anti-MMP13 antibody (abcam,
ab39012, Abcam, Cambridge, MA, USA) and ECL re-
agent (EMD Millipore, Billerica, MA, USA) according
to the manufacturer’s instructions.
miRNA and RNAi transfection
Chondrocytes were plated in 6-well plates at 2 × 105 per
well for transfection. Twenty-four hours after plating, 100
nmol of has-miR-140-5p mimic or 100 nM scrambled 22
nt nucleotides (miR-Scr, with no homology to mammal
genome) or 150 nM inhibitors (designed and synthesized
by RiboBio, Guangzhou, China) were transfected to the
cells with Lipofectamine RNAiMAX (Invitrogen) follow-
ing the manufacturer’s protocol. miR-Scr was transfected
as negative controls. The transfection efficiency was quan-
tified by miR-140-5p qRT-PCR. After 12 hours of incuba-
tion, the cells were used for the following experiments.
Table 1 Primers used for stem-loop reverse transcription or polymerase chain reaction of microRNAs and messenger RNA
Gene name Primer sequences (5′-3′)
Sense GTAGGCACTGCAGATGAGAGAGAGAGAGCGCTGT
Antisense ATCGACAAGCTTCATGCTGCCTTCAGATGAGA
miR-140-5p Stem-loop RT primer GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTACCAT
Sense CGCGCCAGTGGTTTTACCCT
Antisense CCAGTGCAGGGTCCGAGGTA







GAPDH glyceraldehyde 3-phosphate dehydrogenase, MMP-13 metalloproteinase 13
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RNA interference-mediated ERα gene silencing. ERα
gene-specific small interfering RNA (siRNA) (EHU141651)
were purchased from Sigma-Aldrich. Transfection was
performed at a final concentration of 20 nmol/l using
Lipofectamine RNAiMAX (Invitrogen). The expression
level of ERα in cell transfected with ERα RNAi decreased
by 36.4 % respectively when compared with the cells with-
out transfection.
Luciferase assay
All reporter plasmids for transfection were prepared
using the Qiagen plasmid purification kit (Qiagen,
Hilden, Germany). To confirm the activation effect of
miR-140 promoter activity, SW1353 human chondrosar-
coma cells were transiently transfected using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
instructions. Twelve hours after transfection, the cells
were serum starved for 12 hours followed by 4 hours
treatment with or without E2. Then cell lysates were ex-
tracted, and Firefly luciferase activities were measured
using the Luciferase Reporter Assay System (Promega,
Madison, WI, USA) according to the manufacturer’s
protocol. Firefly luciferase activity was normalized to
protein concentrations. Each experiment was performed
three times in triplicate.
Statistics
All experiments were repeated three times with inde-
pendent cultures and similar results were obtained. Real-
time PCR data were given as a threshold cycle (Ct). Fold
changes in gene expression were calculated as 2-ΔΔCt.
Statistical significance was evaluated using a two-tailed
Student’s t test. All data are shown as mean + SE. P <
0.05 was considered statistically significant.
Results
ER induction upregulates miR-140 expression
To determine whether ER regulates the expression of
miRNAs, E2 was added to chondrocytes and miRNA
expression was evaluated by quantitative real-time PCR
(qRT-PCR). Since miR22, miR27b, miR-145, miR-146a,
and miR-140 have been linked to the pathophysiology of
OA [36], we first evaluated the expression of these
miRNA following E2 stimulation. There was no differ-
ence in the expression levels of miR22, miR27b, miR-
145, or miR-146a before or after E2 treatment (Fig. 1a).
However, the expression of miR-140 was upregulated in
a concentration-dependent manner (Fig. 1b) miR-140
expression in primary chondrocytes was rapidly induced
(within 4 hours) by E2 treatment, and expression levels
gradually increased over a 12-hour period (Fig. 1c).
Fig. 1 E2 induced miR-140 expression in time and concentration dependent. a Influence of E2 (10 nM) on OA-related miRNA expression in primary
human articular chondrocytes from female OA patients. b Relative expression of miR-140 in female OA chondrocytes stimulate with different
concentration of E2 for 12 hr. c Kinetics of expression of miR-140 expression treated with E2 (10 nM) for 4, 8, 12 and 24 hr in OA chondrocytes from
female patients. d E2 induction of miR-140 expression was significantly repressed by estrogen receptor alpha RNAi. Data are represented as mean ±
SEM, statistically different from control (*P < 0.05, **P < 0.001). E2 17-β-estradiol, ERα estrogen receptor alpha
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Thus, these data present new evidence that miR-140 is
an early ER-regulated gene. E2 induction of miR-140 ex-
pression was significantly repressed by estrogen receptor
alpha RNAi (Fig. 1d).
E2 downregulates the expression of MMP-13 and
ADAMTS-5 in OA chondrocytes
Previous studies reported that miR-140 expression was
lower in OA cartilage than in normal cartilage [31].
Consistent with these previous reports our study showed
that the expression of MMP-13 was increased in OA
cartilage compared to normal cartilage (Additional file 1:
Figure S1). We studied the effect of E2 on MMP-13 ex-
pression levels in the chondrocytes of OA patients (age
range: 50–70 years, female). Chondrocytes were treated
with different concentrations of E2, and MMP-13 gene
expression was determined by qRT-PCR, with MMP-13
levels normalized to GAPDH levels. E2 significantly
inhibited MMP-13 expression levels in OA chondrocytes
in a dose-dependent manner (Fig. 2a and b).
IL-1β-induced expression of MMP-13 and miR-140 is
blocked by E2
MMP-13 plays an important role in the degradation of
cartilage, especially in IL-1β-stimulated human OA
chondrocytes. Normal chondrocytes treated with IL-1β
displayed degenerative characteristics. To further analyze
the effect of E2 on IL-1β-induced extracellular matrix
(ECM) degradation, chondrocytes were pretreated with
IL-1β to induce MMP-13 expression. The effect of E2
on IL-1β-induced MMP-13 expression at the gene and
protein levels was evaluated by qRT-PCR and immuno-
fluorescence staining, respectively. These results showed
that IL-1β (5 ng/ml) significantly induced MMP-13 ex-
pression at both the mRNA and protein levels. After
treatment with E2 (10 nM), gene and protein expression
of MMP-13 was significantly reduced (Fig. 3a and c).
Subsequently, the expression of miR-140 in IL-1β-
stimulated human chondrocytes was quantified. As ex-
pected, miR-140 expression was significantly decreased
in chondrocytes following IL-1β stimulation. However,
this downregulation of miR-140 expression was blocked
by E2 (Fig. 3b).
E2 modulates MMP-13 transcript expression via miR-140
in human chondrocytes
Our data demonstrated that E2 can suppress MMP-13 ex-
pression and upregulate miR-140 expression. We hypothe-
sized that the inhibiting effect of E2 on MMP-13 may be
mediated by miR-140. To examine the role of miR-140 in
the downregulation of MMP-13 by E2 and to determine
whether modulation of miR-140 can control the pathogen-
esis of OA in vitro, chondrocytes were transfected either
with a miR-140 mimic or a miR-140 inhibitor. After trans-
fection, cells were stimulated with IL-1β for the indicated
times. Pre-transfection of IL-1β-induced chondrocytes
with the miR-140 inhibitor abolished the E2-mediated re-
duction of endogenous levels of MMP-13 transcripts and
proteins (Fig. 4b and d). Interestingly, miR-140 overexpres-
sion by transfection with the miR-140 mimic significantly
reduced the expression of MMP-13 in E2-treated IL-1β-
stimulated human chondrocytes (Fig. 4c and d) Thus, our
results suggest that miR-140 is a crucial regulator of E2-
mediated cartilage homeostasis, where miR-140 enables E2
to suppress IL-1β-induced MMP-13 production. Taken to-
gether, these data strongly indicate that E2 regulates
MMP-13 gene expression in human chondrocytes via the
miR-140 regulatory pathway. Thus, miR-140 expression
was found to be necessary for the significant inhibitory
effect of E2 on IL-1β-induced MMP-13 expression
E2 promotes miR-140 expression by activating ERE
In order to determine whether the upregulation of miR-
140 is transcriptionally dependent on E2, we analyzed
Fig. 2 E2 suppresses MMP-13 expression in female OA chondrocytes. a Relative expression levels of Adamts-5 mRNA 24 hr after E2 treatment in
primary OA chondrocytes from female patients. b Relative expression levels of MMP-13 mRNA 24 hr after E2 treatment in primary OA chondrocytes
from female patients. c Western blot analyses of MMP-13 protein expression in OA chondrocytes from female patients were treated with or without
E2. Data are represented as mean ± SEM. *P < 0.05, **P < 0.001. E2 17-β-estradiol, GAPDH glyceraldehyde 3-phosphate dehydrogenase, MMP-13 metallo-
proteinase 13, mRNA messenger RNA
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the promoter region of miR-140 and found two putative
ERE binding sites for ER in the region upstream of miR-
140, suggesting that ER may modulate miR-140 expres-
sion directly (Fig. 5a). The regulation of miR-140 by ER
was further investigated using a reporter plasmid con-
taining the Firefly luciferase gene under control of the
−495 proximal region sequence upstream of the start
codon for miR-140. E2 stimulation induced activation of
ER, which then positively regulated luciferase activity
(Fig. 5b). We then performed a luciferase assay to con-
firm that the two putative ER binding sites do indeed re-
spond to ER. Compared to the wild-type miR-140
promoter, two miR-140 promoter mutants (mut −336/-
321 and mut −306/-318) exhibited low response to E2.
This indicated that the 495 bp region upstream from
miR-140 is required for its regulation by E2. Altogether,
these results demonstrated that the E2 ligand activates
the transcription factor ER, which then binds to specific
ERE sequences in the promoter region of miR-140 and
positively enhances its transcription.
Discussion
The primary pathogenic event in OA is aberrant remodel-
ing of the cartilage ECM. Estrogen replacement therapy has
been employed to treatment of knee and hip osteoarthritis.
However, the underlying molecular mechanisms by which
estrogen regulates cartilage ECM remain unclear. MMP-13
is known to play a crucial role in IL-1β-induced cartilage
matrix degradation. Moreover, miR-140 inhibits MMP-13
expression in articular chondrocytes [37]. In the present
Fig. 3 Effect of E2 on MMP-13 and miR-140 expression in IL-1β-stimulated chondrocytes. a Relative expression of MMP-13 in normal chondrocytes
stimulated with IL-1β (5 ng/ml) for 4 hr, then treated with 10 nM E2 for 24 hr. b Relative expression of miR-140 in normal chondrocytes pretreated
with IL-1β (5 ng/ml) for 4 hr, then treated with 10 nM E2 for 24 hr. c Immunofluorescence staining of MMP-13 expression in normal chondrocytes
pretreated and untreated with IL-1β (5 ng/ml) for 4 hr, then treated with 10 nM E2 for 24 hr. Data are represented as mean ± SEM. *P < 0.05, **P <
0.001. Cont control, E2 17-β-estradiol, GAPDH glyceraldehyde 3-phosphate dehydrogenase, IL-1β interleukin-1 beta, MMP-13 metalloproteinase 13
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study, we confirmed that E2 has the capacity to downregu-
late MMP-13 transcript and protein levels in OA-diseased
chondrocytes from female patients. We further demon-
strated that E2 treatment suppresses MMP-13 expression
induced by IL-1β in normal chondrocytes, indicating that
E2 may reduce cartilage degradation by suppressing MMP-
13. We also showed that E2 stimulation upregulates the ex-
pression levels of miR-140 in chondrocytes. Thus, we
speculate that the E2-stimulated increase in miR-140 levels
exerts an inhibitory effect on MMP-13.
To further investigate the involvement of miR-140 in
the regulation of MMP-13 by E2 in human articular
chondrocytes, normal chondrocytes were treated with a
miR-140 mimic or a miR-140 inhibitor in the presence
of IL-1β, and MMP-13 transcript levels were quantified.
Treatment with miR-140 dramatically increased the in-
hibitory effect of E2 on MMP-13 in IL-1β-treated chon-
drocytes, whereas treatment with miR-140 inhibitor
dramatically enhanced MMP-13 levels with IL-1β treat-
ment. These findings suggest that miR-140 mediates the
inhibitory effect of E2 on MMP-13.
Cartilage-specific miR-140 was one of the first miR-
NAs found to be abundantly expressed in chondrocytes
and has been shown to critically regulate cartilage devel-
opment and homeostasis. Previous studies reported that
the proximal region upstream of the pri-miR-140 gene
Fig. 4 E2 acts via the ER/miR-140 pathway to suppress IL-1β-mediated catabolic responses in chondrocytes. a Transfection efficiency of miR-140
inhibitor and miR-140 mimic in chondrocytes. Chondrocytes (2.5 × 104 cells per well in a 24-well plate) were planted and transfected with
miR-140 inhibitor, miR-140 mimic, and their negative controls (miR-Scr) up to 24 hr. b Relative MMP-13 mRNA in normal chondrocytes transfected
with miR-140 inhibitor then stimulated with IL-1β (5 ng/ml) for 4 hr, then treated with 10 nM E2 for 24 hr. Inhibitor NC was set to one, as control.
c Relative expression of MMP-13 in normal chondrocytes transfected with miR-140 mimic and pretreated with IL-1β (5 ng/ml) for 4 hr, then
treated with 10 nM E2 for 24 hr. miR-scramble was set to one, as control. d Western blot of MMP-13 expression in normal chondrocytes transfected
with miR-140 inhibitor or miR-140 mimic pretreated and untreated with IL-1β (5 ng/ml) for 4 hr, then treated with10 nM E2 for 24 hr. GAPDH was used
as internal control. Data are represented as mean ± SEM. *P < 0.05, **P < 0.001. E2 17-β-estradiol, GAPDH glyceraldehyde 3-phosphate dehydrogenase,
IL-1β interleukin-1 beta, MMP-13 metalloproteinase 13
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can bind chondrocyte-specific transcriptional factors in
vivo. For example, the expression of miR-140 is directly
regulated by Sox9 [38, 39]. LSox5 and Sox6 can also
control miR-140 expression through a response element
in the miR-140 promoter [40].
ER is known to regulate gene transcription by directly
binding to the promoter of target genes. The miR-140
promoter sequence contains a classical estrogen re-
sponse element (ERE) with the consensus sequence 5′-
GGTCAnnnTGACC-3′ [41, 42]. Thus, miR-140 could
be regulated by binding ER directly. We propose that ER
transcriptional activity regulates miR-140 after estradiol-
mediated ER activation. Our study demonstrated that
miR-140 promoter activity was modulated by estrogen
in chondrocytes. Estradiol stimulated miR-140-driven
luciferase reporter activity, which suggests that ER can
directly activate miR-140 transcription. Therefore, ligand-
dependent activation of ER increased ERE-mediated miR-
140 promoter activity, resulting in MMP-13 suppression.
In menopausal OA conditions, low estrogen levels reduce
the induction of ER/miR-140, resulting in increased
MMP-13 activity. Thus, this study provides novel insights
into how to “fine-tune” ER-dependent signaling for the
control of menopausal OA and may facilitate the develop-
ment of therapeutic approaches based on the modulation
of the ER/miR-140 pathway.
In summary, the present study demonstrates that the
ER/miR-140/MMP-13 pathway is responsible for cartilage
degradation in human OA chondrocytes. E2 regulates
miR-140 and thereby alters MMP-13 activity (Fig. 6).
Fig. 5 E2 stimulation activates human miR-140 promoter activity and is mediated by the −336/-321- and −306/-318- bp sequences. a −495
proximal region sequence upstream of the miR-140 star sequence contains two classical estrogen response elements with the consensus
sequence 5′-GGTCAnnnTGACC-3′. b Luciferase activity in SW1353 cells transfected with miR-140 promoter wide-type (pGL3.-pmiR-140) and two
miR-140 promoter mutants (mut −336/-321 and mut −306/-318), 12 hr after transfection, the cells were serum starved for 12 hr followed by
4-hr treatment with E2 (10 nM). The date are expressed as mean and SEM of three independent experiment. *Statistically different from control
(P < 0.05). ERE estrogen response element, TSS transcription start site
Liang et al. Arthritis Research & Therapy  (2016) 18:105 Page 8 of 10
Results from this study suggest that ER/miR-140 may serve
as a potential therapeutic target for OA treatment.
However, we cannot fully exclude the possibility that other
intracellular signaling pathways are also involved in E2-
stimulated signal transduction. Our findings also prompted
us to investigate whether E2 upregulates miR-140 could at-
tenuates menopausal OA in an OVX mouse model.
Conclusions
Our data demonstrated that ER regulated the expression
of miR-140 in both normal and OA chondrocytes. Fur-
thermore, IL-1β-induced activation of signal transduc-
tion pathways associated with the expression of MMP-
13 downregulated the expression of miR-140. Thus, ER/
miR-140 may play a role in regulating the expression of
MMP-13 in human chondrocytes.
Additional file
Additional file 1: Figure S1. The expression of MMP-13 mRNA level
increased in five OA patients’ articular cartilage tissues. Quantitative
reverse transcription-polymerase chain reaction analysis of the matrix
metalloproteinase 13 (MMP-13) in articular cartilage tissues from five patients
with OA. Figure S2. The gene expressions of cartilage matrix gene for
cartilage development show no effect after E2 treatment. (DOCX 25 kb)
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